Oktreotid Teva 10 mg prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oktreotid teva 10 mg prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje

oktreotid - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - oktreotid 10 mg / 1 viala - oktreotid

Oktreotid Teva 20 mg prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oktreotid teva 20 mg prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje

oktreotid - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - oktreotid 20 mg / 1 viala - oktreotid

Oktreotid Teva 30 mg prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

oktreotid teva 30 mg prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje

oktreotid - prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje - oktreotid 30 mg / 1 viala - oktreotid

Exubera Evropska unija - slovenščina - EMA (European Medicines Agency)

exubera

pfizer limited - insulin human - sladkorna bolezen - zdravila, ki se uporabljajo pri diabetesu - exubera je indiciran za zdravljenje odraslih bolnikov z diabetesom tipa 2, bolezni notadequately nadzira z ustno antidiabetic sredstva in potrebujejo insulin terapija. exubera je prikazano tudi za zdravljenje odraslih bolnikih s tipom 1 sladkorne bolezni, inaddition za dolgo ali vmesne deluje podkožnega insulina, za katere potencialne koristi ofadding pri vdihavanju insulina odtehtajo morebitne pomisleke glede varnosti (glej poglavje 4.

Tyenne Evropska unija - slovenščina - EMA (European Medicines Agency)

tyenne

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresivi - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Lodotra 1 mg tablete s prirejenim sproščanjem Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lodotra 1 mg tablete s prirejenim sproščanjem

mundipharma gmbh - prednizon - tableta s prirejenim sproščanjem - prednizon 1 mg / 1 tableta - prednizon

Lodotra 1 mg tablete s prirejenim sproščanjem Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lodotra 1 mg tablete s prirejenim sproščanjem

mundipharma gmbh - prednizon - tableta s prirejenim sproščanjem - prednizon 1 mg / 1 tableta - prednizon

Lodotra 1 mg tablete s prirejenim sproščanjem Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lodotra 1 mg tablete s prirejenim sproščanjem

mundipharma gmbh - prednizon - tableta s prirejenim sproščanjem - prednizon 1 mg / 1 tableta - prednizon

Lodotra 5 mg tablete s prirejenim sproščanjem Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lodotra 5 mg tablete s prirejenim sproščanjem

mundipharma gmbh - prednizon - tableta s prirejenim sproščanjem - prednizon 5 mg / 1 tableta - prednizon

Lodotra 5 mg tablete s prirejenim sproščanjem Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lodotra 5 mg tablete s prirejenim sproščanjem

mundipharma gmbh - prednizon - tableta s prirejenim sproščanjem - prednizon 5 mg / 1 tableta - prednizon